CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 21 enrolled
Drug / intervention
Levia Narrow Band UVB +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02107482
NCT02107482N/ACompleted
CompareCT.gov

Bilateral Comparator, Sham-Light Source Controlled, Assessor Blinded Clinical Trial of Localized Narrow Band-Ultraviolet B (NB-UVB) (Levia®) Treatment for Plaque-type Psoriasis

Tufts Medical Center·interventional·Posted Apr 8, 2014·Updated Mar 31, 2017

In Brief

A clinical study evaluating Levia Narrow Band UVB and Levia sham/visible-light source for Psoriasis. Completed, enrolled 21 participants across 1 site.

Detailed Summary

The purpose of the study is to test the effect of a localized narrow band ultraviolet (NB-UVB) phototherapy compared to visible light that does not produce UVB on the clearance of psoriasis plaques and resolution of itching. Localized NB-UVB (Levia®) phototherapy device is cleared by the U.S Food and Drug Administration (FDA).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 8, 2014
Enrollment StartDec 1, 2011
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 12.2 years ago

Interventions

Levia Narrow Band UVBdevice

The device's spectral output is is Narrow Band UVB (NB-UVB) (NB-Levia): 308-312 nm

Levia sham/visible-light sourcedevice

the light spectrum is in the range of 400-700nm, the light is produced using the same Levia® device. Levia® enable the user to switch off the UVB light and only produce visible light spectrum.